Form 4: Cytokinetics Director Muna Bhanji Reports Stock Transactions
SEC Form 4 Filing
Director Muna Bhanji reports acquisition and disposal of Cytokinetics Inc. common stock and acquisition of non-qualified stock options.
Summary
- On May 15, 2024, Muna Bhanji, a director of Cytokinetics Inc., reported acquiring 5,600 shares of common stock at $0.
- On the same day, Bhanji disposed of 19,631 shares of common stock.
- Following these transactions, Bhanji beneficially owns 3,636 shares of common stock.
- Bhanji also acquired 3,636 non-qualified stock options with an exercise price of $60.50, exercisable from June 17, 2024, and expiring on May 15, 2034.
Sentiment
Score: 5
Explanation: The sentiment is neutral as it's a standard disclosure of stock transactions. There's no indication of positive or negative sentiment towards the company.
Industry Context
This filing is a routine disclosure of stock transactions by a company insider, which is common in the pharmaceutical industry. These transactions can be influenced by various factors, including personal financial planning and company performance.
Stakeholder Impact
- The transactions may have a minor impact on shareholders, potentially influencing short-term stock price fluctuations.
Key Dates
| Date | Description |
|---|---|
| 05/15/2024 | Date of stock acquisition, disposal, and option acquisition. |
| 06/17/2024 | Date the non-qualified stock options become exercisable. |
| 05/15/2034 | Expiration date of the non-qualified stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.